Clinical characteristics of Lambert-Eaton myasthenic syndrome with positive P/Q-type voltage-gated calcium channel antibody
Tan Y., Zhu L., Wu S., Ding Q., Hu Y., Wu Y., Huang Y., Li K., Li J., Guan Y., Cui L.
The clinical data of 18 patients diagnosed with Lambert-Eaton myasthenic syndrome (LEMS) from Department of Neurology of Peking Union Medical College Hospital from June 2016 to January 2018 were retrospectively analyzed and P/Q-type voltage-gated calcium channel (VGCC) antibodies were detected by radioimmunoprecipitation assay. The VGCC antibody (Ab)-positive rate of LEMS was 15/18, and there were no significant differences in gender, age, disease severity, and tumor prevalence. The disease course was shorter in the antibody-positive group (1.9 years vs 7.6 years, P=0.04), and the clinical manifestation was more complicated in the group with a higher VGCC-Ab. There was a significant correlation between VGCC-Ab and recurrence rate(τ=0.48, P=0.02).